Quantitative Imaging of Tumor-Associated Macrophages and Their Response to Therapy Using 64Cu-Labeled Macrin.

Tumor-associated macrophages (TAMs) are widely implicated in cancer progression, and TAM levels can influence drug responses, particularly to immunotherapy and nanomedicines. However, it has been difficult to quantify total TAM numbers and their dynamic spatiotemporal distribution in a non-invasive and translationally relevant manner. Here, we address this need by developing a pharmacokinetically optimized, 64Cu-labeled polyglucose nanoparticle (Macrin) for quantitative positron emission tomography (PET) imaging of macrophages in tumors. By combining PET with high-resolution in vivo confocal microscopy and ex vivo imaging of optically cleared tissue, we found that Macrin was taken up by macrophages with >90% selectivity. Uptake correlated with the content of macrophages in both healthy tissue and tumors ( R2 > 0.9) and showed striking heterogeneity in the TAM content of an orthotopic and immunocompetent mouse model of lung carcinoma. In a proof-of-principle application, we imaged Macrin to monitor the macrophage response to neo-adjuvant therapy, using a panel of chemotherapeutic and γ-irradiation regimens. Multiple treatments elicited 180-650% increase in TAMs. Imaging identified especially TAM-rich tumors thought to exhibit enhanced permeability and retention of nanotherapeutics. Indeed, these TAM-rich tumors accumulated >700% higher amounts of a model poly(d,l-lactic- co-glycolic acid)- b-polyethylene glycol (PLGA-PEG) therapeutic nanoparticle compared to TAM-deficient tumors, suggesting that imaging may guide patient selection into nanomedicine trials. In an orthotopic breast cancer model, chemoradiation enhanced TAM and Macrin accumulation in tumors, which corresponded to the improved delivery and efficacy of two model nanotherapies, PEGylated liposomal doxorubicin and a TAM-targeted nanoformulation of the toll-like receptor 7/8 agonist resiquimod (R848). Thus, Macrin imaging offers a selective and translational means to quantify TAMs and inform therapeutic decisions.

[1]  R. Advani,et al.  Magnetic Resonance Imaging of Tumor-Associated Macrophages: Clinical Translation , 2018, Clinical Cancer Research.

[2]  Michael F. Cuccarese,et al.  TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy , 2018, Nature Biomedical Engineering.

[3]  R. Weinberg,et al.  Understanding the tumor immune microenvironment (TIME) for effective therapy , 2018, Nature Medicine.

[4]  Steven J. M. Jones,et al.  The Immune Landscape of Cancer , 2018, Immunity.

[5]  R. Weissleder,et al.  Imaging the emergence and natural progression of spontaneous autoimmune diabetes , 2017, Proceedings of the National Academy of Sciences.

[6]  Miles A. Miller,et al.  Prediction of Anti-cancer Nanotherapy Efficacy by Imaging , 2017, Nanotheranostics.

[7]  Miles A. Miller,et al.  Radiation therapy primes tumors for nanotherapeutic delivery via macrophage-mediated vascular bursts , 2017, Science Translational Medicine.

[8]  Heather H Gustafson,et al.  Progress in tumor-associated macrophage (TAM)-targeted therapeutics. , 2017, Advanced drug delivery reviews.

[9]  Miles A. Miller,et al.  In vivo imaging reveals a tumor-associated macrophage–mediated resistance pathway in anti–PD-1 therapy , 2017, Science Translational Medicine.

[10]  R. Keep,et al.  CD163 Expression in Neurons After Experimental Intracerebral Hemorrhage , 2017, Stroke.

[11]  Karen Campbell,et al.  64Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer , 2017, Clinical Cancer Research.

[12]  A. Mills,et al.  Tumor-associated macrophage expression of PD-L1 in implants of high grade serous ovarian carcinoma: A comparison of matched primary and metastatic tumors. , 2017, Gynecologic oncology.

[13]  Ralph Weissleder,et al.  Heterogeneity of macrophage infiltration and therapeutic response in lung carcinoma revealed by 3D organ imaging , 2017, Nature Communications.

[14]  R. Korn,et al.  Correlation between Ferumoxytol Uptake in Tumor Lesions by MRI and Response to Nanoliposomal Irinotecan in Patients with Advanced Solid Tumors: A Pilot Study , 2017, Clinical Cancer Research.

[15]  Hsiao-Ying Wey,et al.  Polyglucose nanoparticles with renal elimination and macrophage avidity facilitate PET imaging in ischaemic heart disease , 2017, Nature Communications.

[16]  D. Ling,et al.  Improved Tumor Uptake by Optimizing Liposome Based RES Blockade Strategy , 2017, Theranostics.

[17]  P. Kantoff,et al.  Cancer nanomedicine: progress, challenges and opportunities , 2016, Nature Reviews Cancer.

[18]  Ian D. McGilvray,et al.  Mechanism of hard nanomaterial clearance by the liver , 2016, Nature materials.

[19]  M. Pittet,et al.  The role of myeloid cells in cancer therapies , 2016, Nature Reviews Cancer.

[20]  Kathryn J Fowler,et al.  Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial. , 2016, The Lancet. Oncology.

[21]  A. J. Tavares,et al.  Analysis of nanoparticle delivery to tumours , 2016 .

[22]  Jedd D. Wolchok,et al.  PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations , 2016, Science Translational Medicine.

[23]  Glen J Weiss,et al.  Phase I Study of PSMA-Targeted Docetaxel-Containing Nanoparticle BIND-014 in Patients with Advanced Solid Tumors , 2016, Clinical Cancer Research.

[24]  R. Weissleder,et al.  Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy. , 2016, Immunity.

[25]  Ashley M. Laughney,et al.  Predicting therapeutic nanomedicine efficacy using a companion magnetic resonance imaging nanoparticle , 2015, Science Translational Medicine.

[26]  Ralph Weissleder,et al.  Tumour-associated macrophages act as a slow-release reservoir of nano-therapeutic Pt(IV) pro-drug , 2015, Nature Communications.

[27]  Zahi A. Fayad,et al.  PET Imaging of Tumor-Associated Macrophages with 89Zr-Labeled High-Density Lipoprotein Nanoparticles , 2015, The Journal of Nuclear Medicine.

[28]  Q. Ye,et al.  A New Approach to Reduce Toxicities and to Improve Bioavailabilities of Platinum-Containing Anti-Cancer Nanodrugs , 2015, Scientific Reports.

[29]  G. von Heijne,et al.  Tissue-based map of the human proteome , 2015, Science.

[30]  Jan Grimm,et al.  Nanoparticles for imaging: top or flop? , 2014, Radiology.

[31]  Jeffrey W Pollard,et al.  Tumor-associated macrophages: from mechanisms to therapy. , 2014, Immunity.

[32]  Miles A. Miller,et al.  Platinum Compounds for High‐Resolution In Vivo Cancer Imaging , 2014, ChemMedChem.

[33]  R. Weissleder,et al.  Imaging macrophages with nanoparticles. , 2014, Nature materials.

[34]  K. Schäkel,et al.  Low-dose irradiation programs macrophage differentiation to an iNOS⁺/M1 phenotype that orchestrates effective T cell immunotherapy. , 2013, Cancer cell.

[35]  Christina S. Leslie,et al.  CSF-1R inhibition alters macrophage polarization and blocks glioma progression , 2013, Nature Medicine.

[36]  P. Libby,et al.  Nanoparticle PET-CT Detects Rejection and Immunomodulation in Cardiac Allografts , 2013, Circulation. Cardiovascular imaging.

[37]  James E Bear,et al.  Nanoparticle clearance is governed by Th1/Th2 immunity and strain background. , 2013, The Journal of clinical investigation.

[38]  F. Yeh,et al.  Decreased reticuloendothelial system clearance and increased blood half-life and immune cell labeling for nano- and micron-sized superparamagnetic iron-oxide particles upon pre-treatment with Intralipid. , 2013, Biochimica et biophysica acta.

[39]  R. Jain,et al.  Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. , 2013, Cancer research.

[40]  Ralph Weissleder,et al.  Polymeric Nanoparticle PET/MR Imaging Allows Macrophage Detection in Atherosclerotic Plaques , 2013, Circulation research.

[41]  M. Zucchetti,et al.  Role of macrophage targeting in the antitumor activity of trabectedin. , 2013, Cancer cell.

[42]  H. Maeda,et al.  The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. , 2013, Advanced drug delivery reviews.

[43]  Stuart S Berr,et al.  PET imaging of tumor associated macrophages using mannose coated 64Cu liposomes. , 2012, Biomaterials.

[44]  R. Weissleder,et al.  89Zr-labeled dextran nanoparticles allow in vivo macrophage imaging. , 2011, Bioconjugate chemistry.

[45]  M. Uesaka,et al.  Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size. , 2011, Nature nanotechnology.

[46]  Daniel G. Anderson,et al.  Therapeutic siRNA silencing in inflammatory monocytes , 2011, Nature Biotechnology.

[47]  Srikanth K. Iyer,et al.  Multimodal silica nanoparticles are effective cancer-targeted probes in a model of human melanoma. , 2011, The Journal of clinical investigation.

[48]  Masahiro Fujita,et al.  Comparison of [11C]-(R)-PK 11195 and [11C]PBR28, two radioligands for translocator protein (18 kDa) in human and monkey: Implications for positron emission tomographic imaging of this inflammation biomarker , 2010, NeuroImage.

[49]  Xiao-Feng Sun,et al.  Expression of the macrophage antigen CD163 in rectal cancer cells is associated with early local recurrence and reduced survival time , 2009, International journal of cancer.

[50]  T. Jacks,et al.  Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase , 2009, Nature Protocols.

[51]  D. Koller,et al.  The Immunological Genome Project: networks of gene expression in immune cells , 2008, Nature Immunology.

[52]  O. Stål,et al.  Breast cancer expression of CD163, a macrophage scavenger receptor, is related to early distant recurrence and reduced patient survival , 2008, International journal of cancer.

[53]  M. Rehli,et al.  Expression of CD68 in Non‐Myeloid Cell Types , 2008, Scandinavian journal of immunology.

[54]  Y. Imai,et al.  Antibodies to CD11b, CD68, and lectin label neutrophils rather than microglia in traumatic and ischemic brain lesions , 2007, Journal of neuroscience research.

[55]  Olli Yli-Harja,et al.  Software for quantification of labeled bacteria from digital microscope images by automated image analysis. , 2005, BioTechniques.

[56]  Tae-You Kim,et al.  Phase I and Pharmacokinetic Study of Genexol-PM, a Cremophor-Free, Polymeric Micelle-Formulated Paclitaxel, in Patients with Advanced Malignancies , 2004, Clinical Cancer Research.

[57]  A. Giatromanolaki,et al.  Liposomal doxorubicin and conventionally fractionated radiotherapy in the treatment of locally advanced non-small-cell lung cancer and head and neck cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  E. Andreeva,et al.  Subendothelial smooth muscle cells of human aorta express macrophage antigen in situ and in vitro. , 1997, Atherosclerosis.

[59]  S. Lee,et al.  Quantitative analysis of total macrophage content in adult mouse tissues. Immunochemical studies with monoclonal antibody F4/80 , 1985, The Journal of experimental medicine.

[60]  F. Hefti High-performance size-exclusion chromatography: a buffer for the reliable determination of molecular weights of proteins. , 1982, Analytical biochemistry.

[61]  S. Snyder,et al.  An improved 2,4,6-trinitrobenzenesulfonic acid method for the determination of amines. , 1975, Analytical biochemistry.

[62]  F. Smith,et al.  COLORIMETRIC METHOD FOR DETER-MINATION OF SUGAR AND RELATED SUBSTANCE , 1956 .